Experimental drug shows promise for Hard-to-Treat cancers

This study tested a drug called PRL3-ZUMAB in 14 people with advanced solid tumors (stomach cancer, liver cancer, or others) that had stopped responding to standard treatments. The drug was given by IV every two weeks for up to 12 doses, with the option to continue if it was helping. The main goals were to see if the drug could shrink tumors or stop them from growing, and to check for side effects. Researchers also looked at genetic markers in the tumors to understand who might benefit most.